Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: A positron emission tomography study with [11C]DASB and (S,S)-[18F]FMeNER-D2

International Journal of Neuropsychopharmacology

Volumn 16, Issue 5, 2013, Pages 937-943

  Nogami, Tsuyoshi ^a,b   Takano, Harumasa ^a   Arakawa, Ryosuke ^a   Ichimiya, Tetsuya ^b   Fujiwara, Hironobu ^a   Kimura, Yasuyuki ^a   Kodaka, Fumitoshi ^a   Sasaki, Takeshi ^a   Takahata, Keisuke ^a   Suzuki, Masayuki ^a,b   Nagashima, Tomohisa ^a   Mori, Takaaki ^a   Shimada, Hitoshi ^a   Fukuda, Hajime ^a   Sekine, Mizuho ^a,b   Tateno, Amane ^b   Takahashi, Hidehiko ^a   Ito, Hiroshi ^a   Okubo, Yoshiro ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Milnacipran; norepinephrine transporter; occupancy; positron emission tomography; serotonin transporter

Indexed keywords

DASB C 11; FMENER D2 F 18; MILNACIPRAN; NORADRENALIN TRANSPORTER; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; THALAMUS;

ADULT; ANTIDEPRESSIVE AGENTS; BENZYLAMINES; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORINE RADIOISOTOPES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84877932794     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001009     Document Type: Article

References (33)

1. Anderson IM (1998). SSRIS vs. tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7 (Suppl. 1), 11-17.
2. 2. Journal of Nuclear Medicine 49, 1270-1276.
3. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25, 871-880.
4. 11C]DASB; comparison with bipolar disorder. Biological Psychiatry 62, 870-877.
5. 11C]O-methylreboxetine and HRRT. Synapse 64, 30-38.
6. 3H] mazindol autoradiography. Journal of Comparative Neurology 304, 419-434.
7. Hayashi M, Mimura M, Otsubo T, Kamijima K (2007). Effect of high-dose milnacipran in patients with depression. Neuropsychiatric Disease and Treatment 3, 699-702.
8. Houle S, Ginovart N, Hussey D, Meyer JH, et al. (2000). Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. European Journal of Nuclear Medicine 27, 1719-1722.
9. 11C](+)McN5652. Biological Psychiatry 51, 715-722.
10. Innis RB, Cunningham VJ, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27, 1533-1539.
11. Jovanovic H, Lundberg J, Karlsson P, Cerin A, et al. (2008). Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39, 1408-1419.
12. Kanemoto K, Matsubara M, Yamashita K, Tarao Y, et al. (2004). Controlled comparison of two different doses of milnacipran in major depressive outpatients. International Clinical Psychopharmacology 19, 343-346.
13. Kasper S, Pletan Y, Solles A, Tournoux A (1996). Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. International Clinical Psychopharmacology 11 (Suppl. 4), 35-39.
14. Kish SJ, Furukawa Y, Chang LJ, Tong J, et al. (2005). Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nuclear Medicine and Biology 32, 123-128.
15. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, et al. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45, 935-944.
16. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
17. Lecrubier Y, Pletan Y, Solles A, Tournoux A, et al. (1996). Clinical efficacy of milnacipran: placebo-controlled trials. International Clinical Psychopharmacology 11 (Suppl. 4), 29-33.
18. 11C]O-methyl reboxetine and PET: problems and progress. Nuclear Medicine and Biology 34, 667-679.
19. Meyer JH, Houle S, Sagrati S, Carella A, et al. (2004). Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Archives of General Psychiatry 61, 1271-1279.
20. 11C]DASB PET imaging study. American Journal of Psychiatry 158, 1843-1849.
21. Okumura K, Furukawa TA (2006). Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. Clinical Drug Investigation 26, 135-142.
22. Papakostas GI, Thase ME, Fava M, Nelson JC, et al. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62, 1217-1227.
23. 11C]DASB and positron emission tomography. Biological Psychiatry 59, 821-828.
24. 2. European Neuropsychopharmacology 15, 517-520.
25. Schou M, Halldin C, Sovago J, Pike VW, et al. (2004). PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53, 57-67.
26. 2. Psychopharmacology 210, 331-336.
27. Suhara T, Takano A, Sudo Y, Ichimiya T, et al. (2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Archives of General Psychiatry 60, 386-391.
28. Takano A, Suzuki K, Kosaka J, Ota M, et al. (2006). A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 185, 395-399.
29. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, et al. (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology 27, 672-676.
30. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, et al. (2004). Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry 55, 320-322.
31. von Frenckell R, Ansseau M, Serre C, Sutet P (1990). Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. International Clinical Psychopharmacology 5, 49-56.
32. Wilson AA, Ginovart N, Schmidt M, Meyer JH, et al. (2000). Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. Journal of Medicinal Chemistry 43, 3103-3110.
33. Yamamoto M, Suhara T, Okubo Y, Ichimiya T, et al. (2002). Age-related decline of serotonin transporters in living human brain of healthy males. Life Sciences 71, 751-757.